CDKN2B and cancer: Mutual exclusivity analysis with genomic alteration data showed that STK11 alterations in cancer patients rarely co-occur with CDK4, CDKN2A, CDKN2B or RB1, supporting a role for STK11 in an oncogenic pathway that is intimately associated with cell cycle function (Fig. 5b).